Invitrogen, The Rat Genome Sequencing Consortium, Catapult Consortium | GenomeWeb

Invitrogen Secures 86 Percent of InforMax Shares

Invitrogen said last week that InforMax share-holders have tendered about 86 percent of the company’s outstanding shares to it so far, a key step to wrapping up its $42 million purchase of the company.

Invitrogen said it needed 85 percent to complete a “short-form” merger that won’t require approval by a vote of shareholders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.